![](/img/cover-not-exists.png)
608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
Naing, A., Mita, M., Komarnitsky, P., Milner, A., von Richter, O., Ogden, J., Piha-Paul, S., Fu, S., Asatiani, E., Kurzrock, R.Volume:
48
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(12)72405-X
Date:
November, 2012
File:
PDF, 64 KB
english, 2012